Isturisa, Oral Treatment for Cushing’s Syndrome, Available in Germany
News
Isturisa (osilodrostat) is now available in Germany to treat adults with endogenous Cushing’s syndrome. The announcement by Recordati Rare Diseases, which acquired rights to Isturisa from its original developer Novartis, follows ... Read more